• Revenue Cycle Management
  • COVID-19
  • Reimbursement
  • Diabetes Awareness Month
  • Risk Management
  • Patient Retention
  • Staffing
  • Medical Economics® 100th Anniversary
  • Coding and documentation
  • Business of Endocrinology
  • Telehealth
  • Physicians Financial News
  • Cybersecurity
  • Cardiovascular Clinical Consult
  • Locum Tenens, brought to you by LocumLife®
  • Weight Management
  • Business of Women's Health
  • Practice Efficiency
  • Finance and Wealth
  • EHRs
  • Remote Patient Monitoring
  • Sponsored Webinars
  • Medical Technology
  • Billing and collections
  • Acute Pain Management
  • Exclusive Content
  • Value-based Care
  • Business of Pediatrics
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Practice Growth
  • Concierge Medicine
  • Business of Cardiology
  • Implementing the Topcon Ocular Telehealth Platform
  • Malpractice
  • Influenza
  • Sexual Health
  • Chronic Conditions
  • Technology
  • Legal and Policy
  • Money
  • Opinion
  • Vaccines
  • Practice Management
  • Patient Relations
  • Careers

Medicare cracks down on false claims

Article

Pfizer allegedly promoted four drugs for off-label indications and caused false claims to be submitted to government health care programs for uses that were not medically accepted indications and therefore not covered by those programs.

A $2.3 billion settlement in September between drugmaker Pfizer and the Department of Justice over illegal marketing practices underscores a recent campaign by government agencies to investigate false claims made to Medicare and Medicaid, according to health care attorneys.

Pfizer allegedly promoted four drugs – Bextra, Geodon, Zyvox and Lyrica – for off-label indications and caused false claims to be submitted to government health care programs for uses that were not medically accepted indications and therefore not covered by those programs, according to the Department of Justice.

Giant pharmaceutical companies aren't the only targets of false claims investigations.

Armstrong advises practices to have a compliance program in place to catch potentially fraudulent claims.

Related Videos